Retrophin Inc. (NASDAQ:RTRX)’s share price dropped 1.2% on Thursday . The stock traded as low as $16.92 and last traded at $17.02, with a volume of 193,985 shares changing hands. The stock had previously closed at $17.22.

A number of equities analysts have commented on RTRX shares. Zacks Investment Research cut shares of Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Leerink Swann reaffirmed a “buy” rating on shares of Retrophin in a research report on Wednesday, May 11th. BMO Capital Markets reaffirmed an “outperform” rating and set a $28.00 price objective (up from $25.00) on shares of Retrophin in a research report on Monday, August 8th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $24.20.

The company’s 50-day moving average price is $18.01 and its 200-day moving average price is $16.10. The company has a market capitalization of $616.71 million and a price-to-earnings ratio of 6.82.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.30. The company earned $33.30 million during the quarter, compared to analysts’ expectations of $32.73 million. Retrophin’s quarterly revenue was up 38.2% on a year-over-year basis. On average, analysts expect that Retrophin Inc. will post $0.09 EPS for the current year.

In related news, EVP Alvin Shih sold 8,750 shares of the stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $17.75, for a total value of $155,312.50. Following the completion of the sale, the executive vice president now directly owns 167,084 shares of the company’s stock, valued at approximately $2,965,741. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

An institutional investor recently raised its position in Retrophin stock. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Retrophin Inc. (NASDAQ:RTRX) by 2.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 149,050 shares of the biopharmaceutical company’s stock after buying an additional 3,900 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.41% of Retrophin worth $2,875,000 as of its most recent filing with the SEC.

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.